{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:01:17Z","timestamp":1775545277695,"version":"3.50.1"},"reference-count":15,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMJ"],"DOI":"10.4274\/mmj.galenos.2024.76508","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T09:54:50Z","timestamp":1717754090000},"page":"140-143","source":"Crossref","is-referenced-by-count":0,"title":["Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases"],"prefix":"10.4274","author":[{"given":"Neslihan","family":"USLU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagan","family":"GUNGOR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonca","family":"TAMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"CAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid","volume":"10","author":"Tasanen","year":"2019","unstructured":"1. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol. 2019;10:1238.","journal-title":"Front Immunol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"001207","DOI":"10.12890\/2019_001207","article-title":"Linagliptin-Associated Alopecia and Bullous Pemphigoid","volume":"6","author":"Someili","year":"2019","unstructured":"2. Someili A, Azzam K, Hilal MA. Linagliptin-Associated Alopecia and Bullous Pemphigoid. Eur J Case Rep Intern Med. 2019;6:001207.","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep. 2014;8:24-8.","DOI":"10.3315\/jdcr.2014.1166"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","unstructured":"4. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131:637-43.","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo","volume":"181","author":"Forssmann","year":"2008","unstructured":"5. Forssmann U, Stoetzer C, Stephan M, et al. Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol. 2008;181:1120-7.","journal-title":"J Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0923-1811(02)00067-1","article-title":"Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid","volume":"30","author":"Giomi","year":"2002","unstructured":"6. Giomi B, Caproni M, Calzolari A, Bianchi B, Fabbri P. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2002;30:116-28.","journal-title":"J Dermatol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.4239\/wjd.v12.i9.1426","article-title":"Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence","volume":"12","author":"Roy","year":"2021","unstructured":"7. Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes. 2021;12:1426-41.","journal-title":"World J Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases","volume":"9","author":"Yoshiji","year":"2018","unstructured":"8. Yoshiji S, Murakami T, Harashima SI, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases. J Diabetes Investig. 2018;9:445-7.","journal-title":"J Diabetes Investig"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.15277\/bjd.2020.262","article-title":"Dipeptidyl peptidase 4 inhibitors and bullous pemphigoid-more evidence of a link: a report of three cases","volume":"20","author":"Randhawa","year":"2020","unstructured":"9. Randhawa A, Torley D, Kerr A, Wylie G. Dipeptidyl peptidase 4 inhibitors and bullous pemphigoid-more evidence of a link: a report of three cases. Br J Diabetes. 2020;20:147-8.","journal-title":"Br J Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12020-020-02272-x","article-title":"Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials","volume":"69","author":"Silverii","year":"2020","unstructured":"10. Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020;69:504-7.","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ajd.13100","article-title":"Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis","volume":"61","author":"Phan","year":"2020","unstructured":"11. Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol. 2020;61:15-21.","journal-title":"Australas J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","unstructured":"12. B\u00e9n\u00e9 J, Moulis G, Bennani I, Auffret M, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175:296-301.","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","unstructured":"13. Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018;154:1152-8.","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.","DOI":"10.1136\/bmj.a180"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","unstructured":"15. Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78:1090-6.","journal-title":"J Am Acad Dermatol"}],"container-title":["Medeniyet Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:04:15Z","timestamp":1775541855000},"score":1,"resource":{"primary":{"URL":"https:\/\/medeniyetmedicaljournal.org\/articles\/doi\/MMJ.galenos.2024.76508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.4274\/mmj.galenos.2024.76508","relation":{},"ISSN":["2149-2042"],"issn-type":[{"value":"2149-2042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}